findmyKOL
Clinical trialNCT05092412Active, not recruitingPhase 2Interventional

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

SponsorYou LuEnrollment30DurvalumabExtensive-stage Small-cell Lung CancerLung Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Henan Provincial People'S Hospital

    Zhengzhou, Henan, China

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Mar 2022
Primary completion
6 Feb 2023
Completion
30 Jun 2027
Last update posted
8 May 2026
Registered enrollment
30
Registry id
NCT05092412
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.